Home > Analyse
Actualite financiere : Actualite bourse

AstraZeneca: positive trial results for blood cancer drug.

(CercleFinance.com) - AstraZeneca's Calquence has showed potential in two chronic lymphocytic leukemia trials, the British drugmaker said on Monday.

Data from two Phase I/II trials presented at the American Society of Hematology annual meeting support the potential of Calquence in this life-threatening disease, which affects tens of thousands of people worldwide, the company said.

AstraZeneca said that Calquence also demonstrated activity in relapsed or refractory mantle cell lymphoma, reaching an 81% overall response rate and a 40% complete response rate in another clinical trial.

Copyright (c) 2017 CercleFinance.com. All rights reserved.